We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Predicts Risk of Preterm Birth Earlier

By LabMedica International staff writers
Posted on 26 Jan 2016
Print article
Image: Fetal fibronectin is a “glue-like” protein that holds the developing baby in the womb (Photo courtesy of Hologic Inc.).
Image: Fetal fibronectin is a “glue-like” protein that holds the developing baby in the womb (Photo courtesy of Hologic Inc.).
Image: The fetal fibronectin test system for predicting preterm labor risk (Photo courtesy of Hologic Inc.).
Image: The fetal fibronectin test system for predicting preterm labor risk (Photo courtesy of Hologic Inc.).
A standard biomarker test offered earlier in pregnancy could potentially help doctors to better identify women at risk of giving birth prematurely, thus enabling health services to focus treatments on women at highest risk.

A number of factors are used to determine if a woman is at risk of giving birth prematurely, including a history of preterm births or late miscarriages. Two further factors which clinicians normally consider are the length of cervix and levels of a biomarker found in vaginal fluid known as fetal fibronectin.

Scientists at King's College London (London, UK) compared measurements of a new fetal fibronectin test in the cervicovaginal fluid of women at 18 to 21 weeks of gestation with measurements made at 22 to 27 weeks of gestation, to see which time period offered the best prediction of spontaneous preterm birth. They also explored whether using a low (10 ng/mL) and high (200 ng/mL) threshold would more accurately classify a women's risk of giving birth prematurely.

Fetal fibronectin was measured using Hologic 10Q system (Hologic; Marlborough, MA, USA). Of the 898 high risk women followed in the study, 8.7% delivered spontaneously before 34 weeks of gestation and only 3.8% of women with concentrations less than 10 ng/mL (tested at 18–21 weeks) delivered before 34 weeks of gestation, a similar rate to that expected in a normal pregnancy. This compared to 2.9% in those tested later (22–27 weeks). In those woman over 200 ng/mL, similar proportions delivered after 34 weeks whether tested early or late (39% versus 43%).

The authors concluded that measuring fetal fibronectin at 18–21 weeks pregnancy appears to offer a similar predictive value to measurements at 22–27 weeks. For both the early and standard tests, there was a noticeable increase in relative risk between the lowest and highest thresholds used in the study. Combining cervical length with the biomarker test was found to improve the diagnostic accuracy further. Low fibronectin concentrations are associated with spontaneous preterm birthrates approaching population background levels.

Andrew A. Shennan, MD, a professor of Obstetrics and lead author of the study, said, “The aim of our study was to find better ways of establishing the risk of women giving birth prematurely in early pregnancy, to enable us to focus on the women most likely to benefit from earlier intervention and close monitoring during pregnancy. Instead of relying on the traditional single threshold later in pregnancy we now can more accurately identify those likely to be normal and those most in need of early interventions, from the first half of pregnancy.” The study was published on January 7, 2016, in the journal Obstetrics and Gynecology.

Related Links:

King's College London
Hologic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.